GET THE APP
Chinese FDA Approved Fungal Glycan-Based Drugs: An Overview of St
Translational Medicine

Translational Medicine
Open Access

ISSN: 2161-1025

+44 1223 790975

Research Article - (2014) Volume 4, Issue 4

View PDF Download PDF

Chinese FDA Approved Fungal Glycan-Based Drugs: An Overview of Structures, Mechanisms and Clinical Related Studies

Zijing Zhou, Zhangrun Han, Yangyang Zeng, Meng Zhang, Yidi Cui, Lingling Xu and Lijuan Zhang*
School of Medicine and Pharmacy, Ocean University of China, Qingdao, China
*Corresponding Author: Lijuan Zhang, Ocean University of China, 5 Yushan Road, Qingdao, China, Tel: +86-532-82031615 Email:

Abstract

Edible mushrooms have been used not only as food and nutraceuticals but also as important ingredients in traditional Chinese medicines for centuries. Pharmaceutical active components from different types of mushrooms have been extracted and studied by scientists all over the world during the past 50 years, and many biological functions, such as antitumor, immunomodulating, anti-oxidative, anti-inflammatory, and hypoglycemic activities, have been reported in peer reviewed English journals. Interestingly, the purified polysaccharides or glycans possess many reported functions of medicinal mushrooms, which make them potential drug candidates. However, glycans are a mixture of polysaccharides having variable numbers of monosaccharides, linkages, and molecular weight distributions as well as multiple biological functions that are hard to conceive as drugs by conventional standard in that a drug should have one structure and one function. On the other hand, multiple ingredients with multiple beneficial effects are essence of traditional Chinese medicines. Subsequently, glycans from different types of medicinal mushrooms are partially purified and trialed as oral and/or injectable drugs in China. Without serious safety concerns of mostly hot water extracted glycans from edible mushrooms and/or the cultured mycelium, eight of them are approved by Chinese Food and Drug Administration (SFDA) and used clinically in China since 1980s. This review article provides basic clinical information of the fungal glycan-based drugs in China and also summarizes structures, functions, and animal studies of fungal glycans conducted by scientists world-wide. Understanding glycan-based drugs at molecular biology level would be central for improving the clinical efficacy of current glycan-based drugs and for designing effective clinical trials of glycan-based drugs in future.

<

Keywords: Fungal glycan base, Chinese FDA, Mushrooms, Polysaccharides

Introduction

Polysaccharides or glycans are located at intracellular, cell membrane, and extracellular spaces serving energy storage, structure, signal transduction, and system regulatory purposes in all living organisms. Among them, animal glycans have been extensively studied at genetic levels. Knocking out a series genes responsible for biosynthesis or modifications of glycans in different animal model systems reveals that animal glycans are indispensable for cell division [1], for animal development [2], and for maintenance of proper immunity and homeostasis in adult animals [3]. For example, endothelial heparan sulfate deficiency impairs L-selectin- and chemokine-mediated neutrophil trafficking during inflammatory responses [4]. Moreover, life-saving drug heparin, one type of glycans purified from animal tissues, remains to be an un-replaceable anticoagulant drug in modern medicine after 78 years of clinical use [2]. Furthermore, 20 different kinds of animal glycan-based drugs have preceded through clinical trials and are used clinically world-wide not only as anticoagulant but also used together with other conventional drugs for cancer treatment with an annual sale over $7 billion dollars [5].These facts indicate glycan-based drugs are not different from other biological drugs either from views of modern molecular biology or from views of their clinical importance.

Like animal cells, fungi synthesize several different types of glycans located in intracellular, cell wall, and extracellular spaces. Moreover, fungi possess several unique glycans that are not made by animal cells, such as chitin, β - glucans, and heteroglycans. In addition, glycanpeptide, glycan-lipid, and glycan-protein complexes isolated from fungi also have potent biological activities. This review article provides basic information of eight fungal glycan-based drugs in China and also summarizes peer-reviewed literatures about structures and biological functions of the fungal glycans at cell- and animal levels along with clinical studies that have been conducted by scientists world-wide.

Eight Fungal Glycans-Based Drugs Approved By Chinese Food and Drug Administration (SFDA)

According to published reports, water-soluble glycans are the most active pharmacological components tested in over 300 kinds of glycans extracted from either plants or fungi [6]. Thus, all eight glycans-based drugs approved by SFDA are hot water extracted glycans either from edible mushrooms and/or from cultured mycelium. Table 1 summaries the basic information of the 8 drugs including imagine of the medicinal mushrooms, starting materials for glycans extraction, type of drugs approved, specified glycan contents, drug number granted by SFDA, clinical indications, and published clinical studies [7-65].

Imagine Specie Source Drug type Glycan content SFDA drug number Clinical applications Ref.
Equation
Ref. [160]		 Ganoderma lucidum Spores Injection Ganoderma lucidum glycans
no less than 90%		 H20003510 Improving endurance of cyclists Dyslipidemia Facial paralysis [7]
[8]
[9]
Equation
Ref.[161]		 Ganoderma Sinensis Fruiting body Tablet Ganoderma Sinensis glycan
no less than 83%		 Z22022112 Mushroom poisoning Leukopenia [10]
[11]
Equation
Ref.[160]		 Lentinus edodes Fruiting body Capsule Lentinan Z20080579 Artificial urticaria [12]
Gastrointestinal cancers [13-18]
Tablet Lentinan
no less than 40%		 Z20026215
Primary liver cancer Hepatitis Malignant
pleural effusion HIV-positive		 [19]
[20,21]
[22-27]
[28]
injection Lentinan
no less than 85%		 H20067183
Equation
Ref.[161]		 Polyporus unbellatus Fruiting body Capsule no less than 40% Z10970134 Hepatitis B Reduce the recurrence of bladder cancer [29-33]
[33]
Injection Polyporus glycan
no less than 90%		 Z32021229
Equation
Ref.[161]		 Polystictus Versicolor Culture of mycelium Capsule Krestin (PSK)
glycans no less than 35%		 H31022501 Acute nonlymphocytic leukemia Colorectal cancer Gastric cancer Lung cancer Primary liver cancer Hepatitis Hyperlipidemia [34]
[35,36]
[37-40]
[41]
[42-44]
[45-50]
[51]
Dropping
pills		 Krestin(PSK)
glycans no less than 38%		 Z20090728
Equation
Ref.[161]		 Poria cocos Culture of Mycelium Injection Pachymaran
no less than 84%		 H20003510 Chronic pulmonary edema Insomnia Alopecia Schizophrenia [52]
[53]
[54]
[55]
Equation
Ref.[160]		 Grifola frondosa Culture of mycelium Capsule Maitake glycans
no less than 40%		 B20020023 Antitumor Impaired Glucose Tolerance
Polycystic ovary syndrome		 [56,162]
[58]
[59]
Equation
Ref. [163]		 Tremella fuciformis Berk Fruiting body Capsule Tremella glycan
no less than 60%		 Z22022048 Mycoplasma pneumonia
Chronic active hepatitis
Antidiabetics
Cancer patients with leukopenia		 [60]
[61]
[62]
[63-65]

Table 1: Eight fungal glycan based-drugs.

As shown in Table 1, glycan contents of the eight approved drugs range from 30% to 93%. There are no specifications about monosaccharide compositions, glycan structures, molecular weight, or biological activity for these approved drugs due to inherent structural diversity of glycans. Taking Ganoderma lucidum glycans as an example, 16 different types of glycans with different monosaccharide compositions, different glycan linkages, and different molecular weight have been purified and identified by applying additional purification schemes when hot water extracted glycans are used as starting materials (Table 2). Therefore, these drugs are not “pure” or a single type of glycans.

Source Extraction method Backbone Major monosaccharide Mw Ref.
Fruiting bodies Hot-water extraction.
Ethanol fractionation, DEAE-cellulose and gel chromatography		 β-Arabinoxyloglucan,
α-Arabinoxyloglucan		 Glucose, xylose, arabinose 4×104 [164]
Fruiting bodies Hot water and alkali extraction Water-soluble
heteroglycans		 Glucose,Galactose,
Mannose,Arabinose,
Xylose, Fucose		 – [165]
Water-insoluble β-glucan Glucose –
Culture of mycelium – Branched β-glucan Glucose – [165]
Fruiting bodies Alkali-extraction
at 25°C and 65°C.		 Linear α-glucan Glucose – [166]
Spores Hot-water extraction.
DEAE-cellulose and
Sephacryl S-200HR		 β-Glucan Glucose 1×104 [130]
Fruiting bodies Hot-water extraction.
DEAE-cellulose and
gel-filtration
chromatography		 α-Heteroglycans
β-Heteroglycans		 Glucose,Galactose,
Rhamnose		 8.3×103 [131]
β-Glucan Glucose 6.3×104
β-Heteroglycan Glucose, Mannose 2.0×105
Extracellular DEAE-Sephacel and
Sephadex G200		 α-Galactose Galactose,Mannose,
Glucose,Arabinose,
Rhamnose		 2.2×104 [167]
Fruiting bodies Hot-water extraction
DEAE-Sepharose Fast-Flow and SephacrylS-300		 α-Galactose,
α-Glucose		 Galactose,
Glucose, Fucose		 1.2×104 [168, 169]
Fruiting bodies Ultra-filtration, DEAE- Sepharose Fast-Flowand Sephacryl S-300 α-Galactose,
β-Glucose		 Galactose,Glucose,
Fucose		 – [170]
Fruiting bodies Hot-water extraction
DEAE-cellulose-32 and
Sephacryl S-200h		 β-Glucan Glucose 5.2×103 [171]
Heteroglycans Glucose,Galactose,
Mannose		 1.54×104
Fruiting bodies Hot-water extraction
DEAE Sepharose Fast-Flow and Sepharose CL-6B		 α-Galactose, Galactose,Glucose,
Fucose		 1.12×104 [172]
β-Glucose
Fruiting bodies Ultrasound/microwave assisted extraction
DEAE Sepharose Fast Flow and Sephacryl S-500		 β-Glucose Glucose, Galactose 2.5×106 [173]
Spores Hot-water extraction, graded ethanol precipitation, DEAE-cellulose and Sephacryl S-300 β-Glucan Glucose 10.3×104 [174]

Table 2: Different glycans isolated from Ganoderma lucidum.

Β - Glucans are glycans that contain only glucose as structural components and are linked with β - glycosidic bonds. β - glucans are the simplest and the most studied fungal glycans. The biologically active fungal β - glucans are those comprising β (1,3) linked-glucose with side-chains of glucose with β (1,6) linkage. As shown in Table 2, the six β - glucans purified from Ganoderma lucidum are either water soluble or insoluble with molecular weight ranged from 5.2 x 103 to 1.0 x 105 Da.Therefore, β - glucans are not pure glycans. β -glucans can bind to six identified receptors on cell surface of immune cells (Figure 1) [66-73]. The β - glucan and receptor interactions can activate multiple signaling transduction pathways directly or indirectly through macrophages, monocytes, dendritic cells, natural killer cells, B-cells, T-cells and neutrophils. β -Glucans also stimulate the release of cytokines, such as tumor necrosis factor (TNF-α) and several interleukins.

translational-medicine-glucans-membrane-immune

Figure 1: Receptors for β-glucans. β -glucans can bind to several membrane receptors on the immune cell surface, such as toll-like recepters 2/6 (TLR2/6), Dectin-1, Fc receptor (FcR), lactosylceramide (LacCer), scavenge receptor (Sc), and complement receptor 3 (CR3). Subsequently, multiple signaling pathways are activated and merged onto important immune regulatory pathways, such as NF- κ B.

Activating the immune cells explain the immunomodulating and antitumor activities of β - glucans. However, not only fungi but also bacteria, plants, and algae synthesize biological active β - glucans. Moreover when present in animal blood circulation, tissues, or organs, most foreign glycans are recognized as sign of bacterium or fungus invasions through a series of receptors on immune cells including those receptors that bind to β - glucans. Most of glycans also have antiinflammatory properties that could not be explained by the glycan/ receptor signal transduction mechanism. Moreover, anti-oxidative and hypoglycemic properties are also common to all biological active glycans. As shown in Table 1, the drug indications of the 8 fungal glycan-based drugs are very different, which suggests the unique glycan compositions, but not the β - glucans alone, might contribute to the observed pharmaceutical effects of the fungal glycan-based drugs. Being not pure might be a reasonable character for glycan-based drugs since glycans produced by nature are never pure even for the simplest β -glucans (see different characteristics of six β -glucans purified from Ganoderma lucidum listed in Table 2. We will briefly review the structure, function, clinical uses, and animal studies (summarized in Table 3) of the 8 fungal glycans and the glycan-based drugs in the next section.

Glycans Models Effects Ref.
Ganoderma lucidum glycans Mouse Enhance phagocytosis and cytotoxicity of macrophages [125]
Mouse Enhance Lymphokine-activated killer cells [125]
Mouse Increase cytotoxic T lymphocyte cytotoxicity and NK activity [134-136]
Mouse Stimulate spleen-cell proliferation and cytokine generation [134,137,138]
Mouse Reduce tumor weight [134]
Mouse Exert antitumor effect on solid tumor induced by Ehrlich’s ascites carcinoma cells [128]
Nude Mouse Reduce Human lung carcinoma xenograft size [140]
Mouse Induce tumor apoptosis and enhance immunological effect [141]
Mouse Enhance scavenging abilities on reactive oxygen species [175]
Rat Reduce ROS production and increase the activity of Manganese superoxide dismutase (Mn-SOD) [142]
Mouse Increase insulin levels and decrease blood glucose [143,144]
Rat Decrease total cholesterol (TC) [143,144]
Mouse Reduce serum triglyceride (TG) [143]
Mouse NO production [139]
Ganoderma sinensis glycan Mouse Enhance levels of IL-2, IL-3, IL-4, interferon γ, TNF α, and IL-2R [112]
Lentinan Mouse Inhibite growth of Sarcoma [78]
Mouse Increase production of cytokine in immune cells [79,80]
Nude Mouse Trigger delayed-type hypersensitivity response against tumor-associated antigens [81]
Chicken Enhance serum antibody titer and promote lymphocyte proliferation [82]
Rat Improve bactericidal ability of peritoneal and alveolar macrophages [83]
Mouse Enhance sensitivity of colon 26 tumor to cis-diamminedichloroplatinum (II) and decrease glutataione transferase expression [84]
Pig Induce high level of alveolar macrophage activation [85]
Mouse Induce TNF-α secretion of murine macrophages [86]
Rat Induce long-term potentiation in the rat dentate gyrus [87]
Mouse Induction of cytotoxic peritoneal exudate cells [176]
Mouse Stimulate the expression of cytokines [88]
Polyporus glycan Mouse Enhance TNF- α , IL-1b, and NO production [177]
Rat Prevente the progression of renal injury and the subsequent renal fibrosis in Aristolochic acid nephropathy [178]
Rat Inhibit bladder carcinogenesis, which may be associated with upregulation of GSTPi and NQO1 in the bladder [179]
Rat Down-regulate AQP2, and down-regulate AQP2 by down-regulating V(2)R [180]
Krestin Rat Suppress metastasis induced by hepatic I/R [100]
Rat Inhibit bone Metastasis of Breast Cancer [101]
Rat Improve GALT inhibition caused by TPN [102]
Pachymaran Mouse Increase thymus and spleen indices, lysozyme, catalase , superoxidase dismutase activities, and total antioxidant capacity. Decrease xanthine oxidase activity and malondialdehyde levels. [118]
Rat Decrease MDA and increase GSH levels in serum cervical of rats with cervical cancer [119]
Rat Increase SOD, CAT, GPx, and GR activities in serum and cervical of rats with cervical cancer [119]
Mouse Enhance antitumor activities [120]
Mouse Increase macrophage activities and PFC, SRFC, DTH, IL-2 , IFN-γ, TNF-α, TCGF levels [121-123]
Maitake glycan Mouse Activate macrophage and induce of IL-1, IL-6 and TNF-a secretion [181]
Mouse Lower plasma cholesterol level [152]
Mouse Activate natural killer and dendritic cells and enhance antitumor immunity [147]
Mouse Protective effect of pancreatic β-cells exerted by decreasing levels of oxidative stress and NO synthesis [148]
Mouse Induce systemic tumor-antigen specific T cell response, increase infiltration of activated T cells into tumor and decrease number of tumor-caused immunosuppressive cells [149]
Rat Significantly lower systolic blood pressure (SBP) in diabetic Sprague-Dawley rats [150]
Rat Inhibite LPS-induced upregulation of NF-κB activation and the production of IL-1β, TNF-α, iNOS, ICAM-1, and COX-2 [151]
Tremella glycan Mouse Have radiation protection properties [154]
Mouse Increase plasma insulin level and the activities of hepatic hexokinase and glucose-6-phosphatase dehydrogenase, and decrease hepatic glucose-6-phosphatase level [155]
Rat Improve cognitive function via regulation of the CREB signaling pathway and cholinergic system in the hippocampus [156,157]
Rat Increase cholinergic activity [158]
Rat Increase fecal neutral steroids, total bile acids excretion, and SCFA productions [159]

Table 3: Animal studies of biological effects of Fungal glycans.

Structural and Functional Studies of Fungal Glycans

Lentinan from Lentinus edodes

Lentinan is a name given to β - glucans purified from Lentinus edodes. The antitumor property of lentinan was first reported by Chihara et al in 1970 [74]. Sasaki and Takasuka demonstrated that the primary structure of lentinan has β - (1-3)-glucose backbone with many (1-6)- β - glucose branches [75].

Letinan-based drugs are available as capsules, tablets, and injections in China. The published clinical reports indicate that these drugs have been used for treating urticaria [12], gastrointestinal cancers [13-18], primary liver cancers [19], hepatitis [20,21], malignant pleural effusion [22-27], and HIV [28].

In 1985, lentinan is approved as an adjuvant for stomach cancer therapy in Japan. The lentinan activates immune cells [76], promotes the T- and B-lymphocyte proliferation, and enhances the activities of NK cells. The lentinan also plays multiple roles in inducing α-interferon production and leukocyte infiltration into tumor tissues [77]. The biological activities of lentinan have been studied by using mouse-,rat-, chicken-, and pig-based animal models [76,78-88]. These animal studies confirm that lentinan stimulate the productions of different cytokines and have antitumor and immunomodulating properties.

Polyporus glycan

Polyporus glycan is extracted from the sclerotium of Polyporus umbellatus. The major component of polyporus glycan is a β - glucan with a (1-3)- β -glucose backbone and (1-6)- β -glucose side chains with a molecular weight of approximately 1.6×105 Da [89].

Polyporus glycans have been commercially available as an immunomodulating drug since 1990. Based on published reports, the polyporus glycan-based capsules are effective in treating hepatitis B [29-33,90,91] and the polyporus glycan-based injections reduce the recurrence of bladder cancer [33]. Polyporus glycan boosts the immune system and have anti-parasite properties [92,93]. It is also used in treating leukemia and liver cancers [94,95]. Study has also shown that Polyporus glycans are effective in protecting liver from certain toxins [95]. Polyporus glycans are also used together with chemotherapy drugs to treat primary lung cancer, liver cancer, cervical cancer, nasopharyngeal carcinoma, esophageal cancer and leukemia.

Polysaccharide-K (PSK) or krestin

PSK or Krestin is a protein bound glycan isolated from cultured mycelium of Polystictus Versicolor. Glucose is the major monosaccharide found in PSK. PSK also contains arabinose, rhamnose, fucose, galactose, mannose, and xylose [96]. The glycans in PSK is highly branched. The molecular weight of PSK is around 1 × 105 Da and the protein component is covalently linked to the β-1,6 glucose side chain.

PSK-based drugs are available as capsules and dropping pills in China. The published clinical reports indicate that these drugs have been used for treating acute nonlymphocytic leukemia [34], colorectal cancers [35,36], gastric cancers [37-40], lung cancer [41], primary liver cancer [42-44], hepatitis[45-50], and hyperlipidemia [51].

PSK has increased the survival time of cancer patients in randomized, control studies, with stomach cancer (meta-analysis of 8,009 patients) [97], colorectal cancer (randomized, controlled study of 448 patients) [98], but PSK has produced mixed results with liver cancer [99]. Rat-based animal studies confirmed the anti-metastasis properties of PSK [100-102].

Three mechanisms are proposed to explain the clinical effectiveness of PSK in suppressing cancer relapse [103]. First, PSK improves host immune-competence by inhibiting the production and also by neutralizing immunosuppressive substances that are increased in cancer. Second, PSK activates immune cells such as lymphocytes, either directly or by regulating the production of various cytokines. Third, PSK acts directly on cancer cells. In addition, the effects of PSK on the production of various cytokines and nitric oxide (NO) have also been reported [104,105].

Ganoderma Sinensis glycans

Ganoderma sinensis glycans are purified from fruiting body of Ganoderma Sinensis. The major bioactive Ganoderma sinensis glycans are α/β -glucans, glycan-protein complex and water-soluble heteroglycans with different combinations of glucose, mannose, galactose, xylose, fucose as well as arabinose. The molecular weight of the glycans ranges from 103 to 106 Da [106].

Ganoderma sinensis glycan-based drugs are available as capsules. Published reports indicated the drug is used for neutralizing mushroom poisoning [10] and stimulate leukocytes productions in leukopenia patients [11] . Further studies showed that Ganoderma sinensis glycans enhance the immune responses in patients with advanced-stage cancer [107,108]. Ganoderma sinensis glycans also have potent antioxidant activities [109-111]. Mouse-based animal studies indicate that Ganoderma sinensis glycans enhance the levels of a variety of citokines [112].

Pachymaran

Pachymaran is a name giving to a heteroglycan isolated from Poria Cocos. Pachymaran consists of glucose, galactose, and mannose. It exhibits antitumor activities both in vitro and in vivo [113,114]. β-Glucan extracted from Poria Cocos is water-insoluble and has no antitumor activity, whereas its phosphorylated water soluble derivatives exhibits strong anti-S-180 tumor activities [115].

Pachymaran used for making the glycan-based injection drugs in China is isolated from mycelium of Poria Cocos. It is used for treating chronic pulmonary edema [52], insomnia [53], alopecia [54], and schizophrenia [55]. It prevents tumor metastasis through its immunomodulatory activities [116,117]. Mouse- and rat-based animal studies showed that pachymaran has potent antioxidative and antitumor activities [118-123].

Ganoderma Lucidum glycans

Ganoderma Lucidium glycans are composed of different variety of glycans as shown in Table 2. Ganoderma Lucidium glycan-based drugs are purified form spores and available as injections. Published reports indicated the drug improves endurance of cyclists [7] and helps patients with dyslipidemia conditions [8]. Interestingly, when combined with glucocorticoid, the drug cures facial paralysis in patients [9].

Mouse and rat-based animal studies showed Ganoderma Lucidium glycans activate different immune cells and stimulate chemokine and cytokine production [108,124-139]. Ganoderma Lucidium glycans also have antitumor [128,140,141], anti-oxidative [124,142], antidiabetic [143,144], and hypolipidemic [143,144] activities.

Maitake glycans

Grifola Frondosa is also called maitake. A bioactive β - glucan fraction termed D-fraction was isolated from both mycelia and fruiting body of Grifola Frondosa by Japanes mycologists in 1984. Grifolanis of maitake glycans is a glycan-protein complex, which is called Wu Rong D-fraction in China. Its glycans mainly consist of glucose along with xylose, fucose, galactose, and mannose. The ratio of protein to glycan in Grifolanis is 7:3. The average molecular weight of Grifolanis is greater than 1x 106 Da. Only Wu Rong D-fraction have antitumor activities [145].

Grifola Frondosa glycans used for drug production is isolated from cultured mycelium. The glycan-based drugs are available as capsules. Published reports indicated the drug is used for cancer treatment [56,57], impaired glucose tolerance conditions [58], and for treating polycystic ovary syndrome [59]. Grifola Frondosa glycans have also been used for cosmetic and other biological purposes [146].

Mouse and rat-based animal studies showed Grifola Frondosa glycans activate different types of immune cells [147] and regulate chemokine and cytokine productions [147-151]. Grifola Frondosa glycans also have antitumor [147], anti-oxidative [148], hypocholesterol [152], and hypo-systolic blood pressure [150] activities.

Tremella glycan

Tremella glycans are isolated from fruiting body of Tremella fuciformis. The most representative glycans in Tremella fuciformis is acidic heteroglucan where α - mannan constituteits the backbone with β - (1,2) xylose, β - (1,2) glucuronic acid, and minor amount of fucose on the side chains. Other glycans include several neutral heteroglycans comprising of xylose, mannose, and galactose.

Tremella glycan-based drugs are available as capsules in China. The drug is used clinically in treating mycoplasma caused pneumonia [60], chronic active hepatitis [61], diabetic [62], leukopenia [63-65] conditions. The drug also promotes neural cell growth and improves memory [153].

Mouse-based animal studies showed tremella glycans have radiation protection properties [154]. Tremella glycans increase plasma insulin level and the activities of hepatic hexokinase and glucose-6-phosphatase dehydrogenase and decrease hepatic glucose-6-phosphatase level [155]. Interestingly, tremella glycans improve cognitive functions through multiple distinctive mechanisms in rats [156-159].

Future Perspectives

There are multiple issues needed to be addressed before fungal glycan-based drugs are accepted by governments and clinicians worldwide, such as how to comprehend the pharmacodynamics of fungal glycan-based drugs at molecular level, how to standardize quality, composition, purity of the highly dispersed glycan molecules, and how to perform reliable pharmacokinetic studies. Compared to conventional small molecule- and protein-based drugs, the advantages of glycan-based drugs are their broad spectrum of therapeutic properties, relatively low toxicity, less drug-resistant issues, and relatively low costs. The disadvantages of glycan-based drugs are the inherited heterogeneity of their structures and functions, lack of tools to do proper structure analyses, and difficulty in establishing structure and function relationships. Thus, developing reliable biological assays and novel structural characterization tools might be critical in understanding the information encoded in the fungal glycans and to perform reliable pharmacokinetic and pharmacodynamic studies.

Acknowledgement

This work was supported by Natural Science Foundation of China (Grant No. 91129706). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  1. Izumikawa T, Kanagawa N, Watamoto Y, Okada M, Saeki M, et al. (2010) Impairment of embryonic cell division and glycosaminoglycan biosynthesis in glucuronyltransferase-I-deficient mice. J BiolChem 285: 12190-12196.
  2. Zhang L (2010) Glycosaminoglycans in Development, Health and Disease. Academic Press, UK.
  3. Lowe JB (2003) Glycan-dependent leukocyte adhesion and recruitment in inflammation. CurrOpin Cell Biol 15: 531-538.
  4. Wang L, Fuster M, Sriramarao P, Esko JD (2005) Endothelial heparan sulfate deficiency impairs L-selectin-and chemokine-mediated neutrophil trafficking during inflammatory responses. Nat Immunol 6:902-910
  5. Hu DJ, Cheong KL, Zhao J, Li SP (2013) Chromatography in characterization of polysaccharides from medicinal plants and fungi. J Sep Sci 36: 1-19.
  6. Rossi P, Buonocore D, Altobelli E, Brandalise F, Cesaroni V, et al. (2014) Improving Training Condition Assessment in Endurance Cyclists: Effects of Ganodermalucidum and Ophiocordycepssinensis Dietary Supplementation. Evid Based Complement Alternat Med 2014: 979613.
  7. Hu M, Zeng W, Tomlinson B (2014) Evaluation of a crataegus-based multiherb formula for dyslipidemia: a randomized, double-blind, placebo-controlled clinical trial. Evid Based Complement Alternat Med 2014: 365742.
  8. Song LX (2010) Clinical Effect of GLPS injection combined with glucocorticoid in treatment of facial paralysis. Cap J Pharm:27
  9. HE JY (1984) Clinical manifestations of three kinds of poisonous mushroom poisoning and Ganoderma's treatment effect. Guangdong health and epidemic prevention information:102-105
  10. Mao HH (1988) Clinical Observation of G. sinensis polysaccharide in treatment of Leukopenia(27 cases). Chinese Journal of Industrial Hygiene and Occupational Diseases:251
  11. Zeng T, Ding Z, Zhao F (2006) Clinical Effect of Mizolastine Combined LentinusEdodes Mycelia Polysacharide in Treatment of Factitious urticaria. Chinese Journal of Dermatology 20:i1
  12. Yoshino S, Oka M (2008) [Clinical trial of non-specific immunotherapy using Lentinan in advanced or recurrent gastric cancer]. GanTo Kagaku Ryoho 35: 2239-2243.
  13. Chang YF, Tang AM, Wang JF, Ge MD (2008) Clinical Effect of lentinan in adjuvant therapy of elderly patients with advanced gastric cancer and colorectal cancer. journal of Modern integrative medicine:4375-4376
  14. Wang D, Pan C, Han S, Yu X (2012) Clinical Effect of lentinan injection in improving the quality of life in patients with gastrointestinal cancer after chemotherapy. Journal of Practical Medicine:4143-4145
  15. Wang L, Wang JR, Wang KM, Wang ZX (2013) Clinical observation of lentinan injection immunomodulatory effects of gastric cancer. Journal of Hainan Medical:3610-3612
  16. Wang YH, Meng GL (2012) Clinical observation of lentinan combined XELOX regimen in treatment of advanced colorectal cancer. journal of Chinese pharmaceutical and clinical 12:1483-1485
  17. Zhang GY, Song ZY, Gao MH, Qin YZ (2005) Clinical Effect of lentinan in adjuvant therapy of colon cancer patients after chemotherapy. Journal of Weifang Medical College:122-123
  18. Bin YZ, Yao HC (1999) Clinical observation of lentinan in treatment of primary liver cancer. Chinese Journal of Clinical Oncology 26:393-394
  19. . Wang JX (1994) Clinical observation of lentinan in treatment of 60 cases of hepatitis B. journal of Chinese medicine 16:23-24
  20. Wu BC, Yang JL (1993) ?clinical trial summary of lentinan injection in treatment of 108 cases of chronic viral hepatitis. Fujian Journal of Traditional Chinese Medicine 24:10-13
  21. Zhong MW, Tang RD, Yang JS, Mo GY (2006) Clinical observation of lentinan combined HCPT in treatment of malignant pleural effusion. Chinese Journal of emergency medicine 15:597-598
  22. Guo QX, Su WZ (2007) Clinical observation of lentinan injection in treatment of malignant pleural effusion. Medical Review:2032-2033
  23. Xia CW, Chen WP, Xu L, Xu XF (2011) Clinical observation of intrathoracic injection of cisplatin and lentinan in treatment of elderly malignant pleural effusion. Journal of Clinical Pulmonary Medicine:225-226
  24. Gao SY (2010) Efficacy analysis of lentinan treatment of malignant pleural effusion (66 cases). journal of Shanxi Medical University:145-146
  25. Nie DD, Li L, Xue PL, Xiong Y (2010) Clinical observation and research on the clinical value of Lentinan combined cisplatin or cisplatin alone in the treatment of malignant pleural effusion. journal of Sichuan Medical:1267-1269
  26. Chang XH, Shao P, Huang XB, Xu W (2013) Clinical Research on cisplatin combined lentinan in local therapy of malignant pleural effusion. New Medicine:840-842
  27. Gordon M, Bihari B, Goosby E, Gorter R, Greco M, et al. (1998) A placebo-controlled trial of the immune modulator, lentinan, in HIV-positive patients: a phase I/II trial. J Med 29: 305-330.
  28. Liu LF (2009) Clinical observation of PUPS combined hepatitis B vaccine in treatment of 128 cases of chronic hepatitis B. Clin Med:15-16
  29. Zhang XY, Wei L, Lv XX (1994) Clinical observation of PUPS in treatment of 36 cases of chronic hepatitis B. journal of Xuzhou Medical College:240-241
  30. Wu WX (1994) Clinical observation of Polyporus Polysaccharide combined small amount of interferon in treatment of chronic hepatitis B. Zhejiang journal of INTEGRATIVE MEDICINE:29-30
  31. Yang JL (1995) Polyporus Polysaccharide combined Hepatitis B Vaccinein treatment of chronic hepatitis B. Chinese Journal of Digestion:238-239
  32. Liang SS, Huang JC (1999) The clinical application of PUPS. Chinese Journal of Hospital Pharmacy:37-39
  33. Ohno R, Yamada K, Masaoka T, Ohshima T (1984) A randomized trial of chemoimmunotherapy of acute nonlymphocytic leukemia in adults using a protein-bound polysaccharide preparation. Cancer ImmunolImmunother 18:149-154
  34. Sakamoto J, Morita S, Oba K, Matsui T (2006) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer ImmunolImmunother 55:404-411
  35. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, et al. (1992) Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130.
  36. Choi JH, Kim YB, Lim HY, Park JS, Kim HC, et al. (2007) 5-fluorouracil, mitomycin-C, and polysaccharide-K adjuvant chemoimmunotherapy for locally advanced gastric cancer: the prognostic significance of frequent perineural invasion. Hepatogastroenterology 54: 290-297.
  37. Ueda Y, Fujimura T, Kinami S, Hirono Y (2006) A randomized phase III trial of postoperative adjuvant therapy with S-1 alone versus S-1 plus PSK for stage II/IIIA gastric cancer: Hokuriku-Kinki Immunochemo-Therapy Study Group-Gastric Cancer (HKIT-GC). Jpn J ClinOncol 36:519-522
  38. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, et al. (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer ImmunolImmunother 56: 905-911.
  39. Zhong Y, Zou Q, Zhang LY (2001) Clinical observation on attenuated effect of PSP in the treatment of gastric cancer after chemotherapy. Liaoning Journal of Traditional Chinese Medicine:668-669
  40. Huang CJ, Cai SY (2000) Clinical efficacy of PSP capsule combined chemotherapy in the treatment of advanced lung cancer. Medicine of anthology 19:871-872
  41. Wang B, Jia YS, Jia YJ, Zhao C (2009) Clinical observation of Synergy and Attenuation of Versicolor capsule in the treatment of advanced hepatocellular carcinoma. World Chinese Medicine:202-203
  42. Zhu YJ, Qian WX (1994) Clinical report of Dong Fang Yunzhi capsules combined compound Muji granules in the treatment of phase ?primary liver cancer(32 cases). Shanghai Journal of Traditional Chinese Medicine:43
  43. Cheng WW (1994) Clinical application reports of PSK in treatment of advanced cancer(75 cases). Journal of Contemporary Oncology:307-308
  44. Zhang W, Xing LJ, Wang YN, Wang Y (1994) Clinical observation of Dong Fang Yunzhi capsules in the treatment of viral hepatitis. Shanghai Journal of Traditional Chinese Medicine:35-36
  45. Recent clinical and immunological observation of Baishanversicolor polysaccharide in the treatment of chronic liver disease. Jilin Health Journal:1-6
  46. Shao W, Zhao DM, Zhu QY (1980) PSK preparation and its clinical efficacy for chronic hepatitis. Chinese Journal of Pharmaceuticals:25-27
  47. Mu GY, Lu Y, Wang JR, Xiong HC (1984) Clinical observation of versicolor intracellular polysaccharide in the treatment of 47 cases of chronic hepatitis B. Antibiotics:129-131
  48. Luo ZQ, Zhong MF, Hu YM, Zeng GY (1985) Clinical observation of versicolor intracellular polysaccharide in the treatment of 30 cases of chronic hepatitis B. Antibiotics:53-55
  49. Lu Y, Mu GY (1987) Clinical observation of versicolor intracellular polysaccharide in the treatment of 240 cases of chronic hepatitis B. Antibiotics:101-104
  50. Rao G, Tang XW (2007) Clinical observation of versicolor intracellular polysaccharide in the treatment hyperlipidemia. Chongqing Medical journal:1306-1307
  51. Zhang L, Wang SL (2004) Clinical Effect of Poria in treating heart failure edema in patients with Chronic pulmonary heart disease(54 cases ). Journal of Practical Traditional Chinese Internal Medicine 18:164
  52. Fan GB (2006) High-dose Poria in treatment of insomnia(24 cases). Research of Traditional Chinese Medicine:35-36
  53. Liu C (1996) Poria in treatment of alopecia(23cases). Journal of Hubei Traditional Chinese Medicine:58
  54. Zhang YQ, Luo KL, Zhao EH, Li QF (1982) Changes in IgA and serum ceruloplasmin in chronic schizophrenia with treatment of Poria. Shanxi Journal of Medicine:14-15
  55. Deng G, Lin H, Seidman A, Fornier M, D'Andrea G, et al. (2009) A phase I/II trial of a polysaccharide extract from Grifolafrondosa (Maitake mushroom) in breast cancer patients: immunological effects. J Cancer Res ClinOncol 135: 1215-1221.
  56. LIU A, ZANG LH, SUN QJ (2008) Clinical observation of effect on GrifolaFrondosa Amylose against tumor. Journal of Shandong Institute of Light Industry: Science and Technology 22:43-45
  57. Ren HY, Wang HF, Yuan FW, Zhang JP (2002) Clinical observation of Maitake capsules in the treatment of IGT. The Third International Conference of Diabetes., Beijing China, p 3
  58. Chen JT, Tominaga K, Sato Y, Anzai H (2010) Maitake mushroom (Grifolafrondosa) extract induces ovulation in patients with polycystic ovary syndrome: a possible monotherapy and a combination therapy after failure with first-line clomiphene citrate. J Altern Complement Med 16:1295-1299
  59. Zhao XH (2009) Clinical observation of Tremella Polysaccharide Enteric-coated Capsules combined azithromyc in treatment of mycoplasma pneumonia. Chinese Medicine Modern Distance Education of China: 111.
  60. Li QZ, Huang CJ, Jiao LH, Pan SJ (2006) Clinical studies of Tremella Polysaccharide Enteric-coated Capsules for the treatment of chronic active hepatitis. Infectious Disease Information 19:201-202.
  61. Kiho T, Kochi M, Usui S, Hirano K, Aizawa K, et al. (2001) Antidiabetic effect of an acidic polysaccharide (TAP) from Tremellaaurantia and its degradation product (TAP-H). Biol Pharm Bull 24: 1400-1403.
  62. Cheng GZ (1982) Clinical observation of Tremella Polysaccharide for the cancer patients with leukopenia(40 cases). Antibiotics:52-55
  63. Yang S, Zhou FM, Li M, Zhao WJ (1983) Clinical observation of Tremella Polysaccharide on immune function of white blood cells. Journal of Kunming Medical College:9-15
  64. Wang Y, Sun HH, Li XQ (2011) Clinical observation of Tremella Polysaccharide Enteric-coated Capsules in treatment of interferon-induced Leukopenia. Hebei Medicine:411
  65. Kariya Y, Okamoto N, Fujimoto T, Inoue N (1991) Lysis of fresh human tumor cells by autologous peripheral blood lymphocytes and tumor-infiltrating lymphocytes activated by PSK. Jpn J Cancer Res 82:1044-1050
  66. Nio Y, Shiraishi T, Tsubono M, Morimoto H (1991) In vitro immunomodulating effect of protein-bound polysaccharide, PSK on peripheral blood, regional nodes, and spleen lymphocytes in patients with gastric cancer. Cancer ImmunolImmunother 32:335-341
  67. Vánky F, Wang P, Klein E (1992) The polysaccharide K (PSK) potentiates in vitro activation of the cytotoxic function in human blood lymphocytes by autologous tumour cells. Cancer ImmunolImmunother 35: 193-198.
  68. Ebina T, Kohya H (1988) Antitumor effector mechanism at a distant site in the double grafted tumor system of PSK, a protein-bound polysaccharide preparation. Jpn J Cancer Res 79: 957-964.
  69. Tsuru S, Nomoto K (1983) Effects of PSK on specific tumor immunity to syngeneic tumor cells. J Clin Lab Immunol 10: 215-219.
  70. Algarra I, Collado A, Garrido F (1997) Protein bound polysaccharide PSK abrogates more efficiently experimental metastases derived from H-2 negative than from H-2 positive fibrosarcoma tumor clones. J ExpClin Cancer Res 16:373-380
  71. Baba N, Yamaguchi Y, Sato Y, Takayama T (1990) The enhancement of tumoricidal activities of macrophages by protein-bound polysaccharide in tumor bearing mice. Biotherapy 4:123-128
  72. Kato H, Kin R, Yamamura Y, Tanigawa M (1987) Tumor inhibitory effect of polymorphonuclear leukocytes (PMN) induced by PSK in the peritoneal cavity of tumor-bearing mice. J Kyoto PrefUniv Med 96:927-937
  73. Chihara G, Hamuro J, Maeda Y, Arai Y, Fukuoka F (1970) Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinusedodes (Berk.) Sing. (an edible mushroom). Cancer Res 30: 2776-2781.
  74. Sait OH, Ohki T, Takasuka N, Sasaki T (1977) A< sup> 13 CN. MR-Spectral study of a gel-forming, branched (1? 3)-$\beta$-d-glucan,(lentinan) from< i>lentinusedodes, and its acid-degraded fractions. Structure, and dependence of conformation on the molecular weight. Carbohyd Res 58:293-305
  75. Hamuro J, Röllinghoff M, Wagner H (1980) Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the beta(1 leads to 3) glucan-type lentinan and its analogues. Immunology 39: 551-559.
  76. Yan J, Vetvicka V, Xia Y, Coxon A, Carroll MC, et al. (1999) Beta-glucan, a "specific" biologic response modifier that uses antibodies to target tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). J Immunol 163: 3045-3052.
  77. Chihara G, Hamuro J, Maeda Y, Arai Y, Fukuoka F (1970) Fractionation and purification of the polysaccharides with marked antitumor activity, especially lentinan, from Lentinusedodes (Berk.) Sing. (an edible mushroom). Cancer Res 30: 2776-2781.
  78. XuJie H, Na Z, SuYing X, ShuGang L (2008) Extraction of BaChu mushroom polysaccharides and preparation of a compound beverage. CarbohydPolym 73:289-294
  79. Lull C, Wichers HJ, Savelkoul HF (2005) Antiinflammatory and immunomodulating properties of fungal metabolites. Mediators Inflamm 2005: 63-80.
  80. Suzuki M, Iwashiro M, Takatsuki F, Kuribayashi K (1994) Reconstitution of anti-tumor effects of lentinan in nude mice: roles of delayed-type hypersensitivity reaction triggered by CD4-positive T cell clone in the infiltration of effector cells into tumor. Jpn J Cancer Res 85:409-417
  81. Guo Z, Hu Y, Wang D, Ma X, Zhao X, et al. (2009) Sulfated modification can enhance the adjuvanticity of lentinan and improve the immune effect of ND vaccine. Vaccine 27: 660-665.
  82. Markova N, Kussovski V, Radoucheva T, Dilova K, Georgieva N (2002) Effects of intraperitoneal and intranasal application of Lentinan on cellular response in rats. IntImmunopharmacol 2: 1641-1645.
  83. Murata T, Hatayama I, Kakizaki I, Satoh K, Sato K, et al. (1996) Lentinan enhances sensitivity of mouse colon 26 tumor to cis-diamminedichloroplatinum (II) and decreases glutathione transferase expression. Jpn J Cancer Res 87: 1171-1178.
  84. Drandarska I, Kussovski V, Nikolaeva S, Markova N (2005) Combined immunomodulating effects of BCG and Lentinan after intranasal application in guinea pigs. IntImmunopharmacol 5: 795-803.
  85. Kerékgyártó C, Virág L, Tankó L, Chihara G, Fachet J (1996) Strain differences in the cytotoxic activity and TNF production of murine macrophages stimulated by lentinan. Int J Immunopharmacol 18: 347-353.
  86. Edagawa Y, Smriga M, Nishiyama N, Saito H (2001) Systemic administration of lentinan, a branched beta-glucan, enhances long-term potentiation in the rat dentate gyrus in vivo. NeurosciLett 314: 139-142.
  87. Liu F, Ooi VE, Fung MC (1999) Analysis of immunomodulating cytokine mRNAs in the mouse induced by mushroom polysaccharides. Life Sci 64: 1005-1011.
  88. Zong A, Cao H, Wang F (2012) Anticancer polysaccharides from natural resources: a review of recent research. CarbohydrPolym 90: 1395-1410.
  89. Yan SC (1988) [Clinical and experimental research on Polyporusumbellatus polysaccharide in the treatment of chronic viral hepatitis]. Zhong Xi Yi Jie He ZaZhi 8: 141-143, 131.
  90. Xiong LL (1993) [Therapeutic effect of combined therapy of Salvia miltiorrhizae and Polyporusumbellatus polysaccharide in the treatment of chronic hepatitis B]. Zhongguo Zhong Xi Yi Jie He ZaZhi 13:533-535.
  91. Zhang YH, Liu YL, Yan SC (1991) [Effect of Polyporusumbellatus polysaccharide on function of macrophages in the peritoneal cavities of mice with liver lesions]. Zhong Xi Yi Jie He ZaZhi 11: 225-226, 198.
  92. Yang LJ, Wang RT, Liu JS, Tong H, Deng YQ, et al. (2004) [The effect of polyporusumbellatus polysaccharide on the immunosuppression property of culture supernatant of S180 cells]. Xi Bao Yu Fen ZiMian Yi Xue ZaZhi 20: 234-237.
  93. Wu GS, Zhang LY, Okuda H (1997) [Inhibitive effect of umbellatuspolyporus polysaccharide on cachexic manifestation induced by toxohormone-L in rats]. Zhongguo Zhong Xi Yi Jie He ZaZhi 17: 232-233.
  94. Lin YF, Wu GL (1988) [Protective effect of Polyporusumbellatus polysaccharide on toxic hepatitis in mice]. Zhongguo Yao Li Xue Bao 9: 345-348.
  95. Wang HX, NG TB, Liu WK, Ooi VE (1996) Polysaccharide-peptide complexes from the cultured mycelia of the mushroom Coriolusversicolor and their culture medium activate mouse lymphocytes and macrophages. Int J Biochem Cell Biol 28:601-607
  96. Oba K, Teramukai S, Kobayashi M, Matsui T, Kodera Y, et al. (2007) Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curative resections of gastric cancer. Cancer ImmunolImmunother 56: 905-911.
  97. Mitomi T, Tsuchiya S, Iijima N, Aso K, Suzuki K, et al. (1992) Randomized, controlled study on adjuvant immunochemotherapy with PSK in curatively resected colorectal cancer. The Cooperative Study Group of Surgical Adjuvant Immunochemotherapy for Cancer of Colon and Rectum (Kanagawa). Dis Colon Rectum 35: 123-130.
  98. Suto T, Fukuda S, Moriya N, Watanabe Y, Sasaki D, et al. (1994) Clinical study of biological response modifiers as maintenance therapy for hepatocellular carcinoma. Cancer ChemotherPharmacol 33 Suppl: S145-148.
  99. Tamagawa K, Horiuchi T, Wada T, Bannai K, Ando T (2012) Polysaccharide-K (PSK) may suppress surgical stress-induced metastasis in rat colon cancer. Langenbecks Arch Surg 397: 475-480.
  100. Iino Y, Yokoe T, Maemura M, Takei H, Horiguchi J, et al. (1997) A New Endocrine Therapy Strategy for Bone Metastasis of Breast Cancer: The Effect of Biological Response Modifiers and 22-Oxacarcitriol on Animal Models. Breast Cancer 4: 311-313.
  101. Nakasaki H, Tajima T, Mitomi T, Fujii K, Kamijoh A (1996) [Countermeasures for hypofunction of gut associated lymphoid tissue during TPN in rats]. Nihon ShokakibyoGakkaiZasshi 93: 806-812.
  102. Maehara Y, Tsujitani S, Saeki H, Oki E, Yoshinaga K, et al. (2012) Biological mechanism and clinical effect of protein-bound polysaccharide K (KRESTIN(®)): review of development and future perspectives. Surg Today 42: 8-28.
  103. Hirose K, Zachariae CO, Oppenheim JJ, Matsushima K (1990) Induction of gene expression and production of immunomodulating cytokines by PSK in human peripheral blood mononuclear cells. Lymphokine Res 9: 475-483.
  104. Asai K, Kato H, Kimura S, Mukai S, Kawahito Y, et al. (1996) Induction of gene expression for nitric oxide synthase by immunomodulating drugs in the RAW264.7 murine macrophage cell line. Cancer ImmunolImmunother 42: 275-279.
  105. Nie S, Zhang H, Li W, Xie M (2013) Current development of polysaccharides from< i>Ganoderma: Isolation, structure and bioactivities. Bioactive Carbohydrates and Dietary Fibre 1:10-20
  106. Gao Y, Zhou S, Jiang W, Huang M, Dai X (2003) Effects of ganopoly (a Ganodermalucidum polysaccharide extract) on the immune functions in advanced-stage cancer patients. Immunol Invest 32: 201-215.
  107. Gao Y, Gao H, Chan E, Tang W, Xu A, et al. (2005) Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganodermalucidum, in mice. Immunol Invest 34: 171-198.
  108. Mau J, Tsai S, Tseng Y, Huang S (2005) Antioxidant properties of hot water extracts from< i>GanodermatsugaeMurrill. LWT-Food science and Technology 38:589-597
  109. Mau J, Tsai S, Tseng Y, Huang S (2005) Antioxidant properties of methanolic extracts from< i>Ganodermatsugae. Food Chem 93:641-649
  110. Tseng Y, Yang J, Mau J (2008) Antioxidant properties of polysaccharides from< i>Ganodermatsugae. Food Chem 107:732-738
  111. Li Q, Wang X, Chen Y, Lin J, Zhou X (2010) Cytokines expression induced by Ganodermasinensis fungal immunomodulatory proteins (FIP-gsi) in mouse spleen cells. ApplBiochemBiotechnol 162: 1403-1413.
  112. Huang Q, Jin Y, Zhang L, Cheung PCK (2007) Structure, molecular size and antitumor activities of polysaccharides from Poriacocos mycelia produced in fermenter. CarbohydPolym 70:324-333
  113. RuiDian K, ShunFa L, Yi C, ChuRong J (2010) Analysis of chemical composition of polysaccharides from Poriacocos Wolf and its anti-tumor activity by NMR spectroscopy. CarbohydPolym 80:31-34
  114. Chen X, Xu X, Zhang L, Zeng F (2009) Chain conformation and anti-tumor activities of phosphorylated (1? 3)-$\beta$-d-glucan fromPoriacocos. CarbohydPolym 78:581-587
  115. Zjawiony JK (2004) Biologically active compounds from Aphyllophorales (polypore) fungi. J Nat Prod 67: 300-310.
  116. Chen YY, Chang HM (2004) Antiproliferative and differentiating effects of polysaccharide fraction from fu-ling (Poriacocos) on human leukemic U937 and HL-60 cells. Food ChemToxicol 42: 759-769.
  117. Wei XJ, Hu TJ, Chen JR, Wei YY (2011) Inhibitory effect of carboxymethylpachymaran on cyclophosphamide-induced oxidative stress in mice. Int J BiolMacromol 49: 801-805.
  118. Chen Y, Chen X, Tang Q, Wang W, et al. (2010) Simultaneous extraction of polysaccharides from Poriacocos by ultrasonic technique and its inhibitory activities against oxidative injury in rats with cervical cancer. CarbohydPolym 79:409-413
  119. Wang Y, Zhang L, Li Y, Hou X, Zeng F (2004) Correlation of structure to antitumor activities of five derivatives of a beta-glucan from Poriacocossclerotium. Carbohydr Res 339: 2567-2574.
  120. Zhang XJ, Xu J, Lin ZB (2002) Carboxymethylpachymaran impact on immune function in mice. Chi PharmaJ:35-38
  121. Chen CX (2001) Antitumor activity and immune effector of Carboxymethylpachymaran. Edible fungi Journal:39-44
  122. Chen CX, Zhao DM, Zhang XJ, Lin ZB (2002) Anti-tumor experiments of Carboxymethylpachymaran. Fuj J Traditi Chi Med:38-40
  123. You YH, Lin ZB (2002) Protective effects of Ganodermalucidum polysaccharides peptide on injury of macrophages induced by reactive oxygen species. ActaPharmacol Sin 23: 787-791.
  124. Zhu XL, Chen AF, Lin ZB (2007) Ganodermalucidum polysaccharides enhance the function of immunological effector cells in immunosuppressed mice. J Ethnopharmacol 111: 219-226.
  125. Zhang Q, Lin Z (1999) The antitumor activity of Ganodermalucidum (Curt.: Fr.) P. Karst.(Ling Zhi)(Aphyllophoromycetideae) polysaccharides is related to tumor necrosis factor-a and interferon-?. Int J Med Mushrooms1 :1-10.
  126. Cao LZ, Lin ZB (2002) Regulation on maturation and function of dendritic cells by Ganodermalucidum polysaccharides. ImmunolLett 83: 163-169.
  127. Joseph S, Sabulal B, George V, Antony KR, Janardhanan KK (2011) Antitumor and anti-inflammatory activities of polysaccharides isolated from Ganodermalucidum. Acta Pharm 61: 335-342.
  128. Harris PJ, Henry RJ, Blakeney AB, Stone BA (1984) An improved procedure for the methylation analysis of oligosaccharides and polysaccharides. Carbohydr Res 127: 59-73.
  129. Bao X, Liu C, Fang J, Li X (2001) Structural and immunological studies of a major polysaccharide from spores of Ganodermalucidum (Fr.) Karst. Carbohydr Res 332: 67-74.
  130. Bao XF, Wang XS, Dong Q, Fang JN, Li XY (2002) Structural features of immunologically active polysaccharides from Ganodermalucidum. Phytochemistry 59: 175-181.
  131. Ooi LS, Ooi VEC, Fung MC (2002) Induction of gene expression of immunomodulatory cytokines in the mouse by a polysaccharide from Ganodermalucidum (Curt.: Fr.) P. Karst.(Aphyllophoromycetideae). Int J Med Mushrooms 4 : 1-9.
  132. Wang Y, Khoo K, Chen S, Lin C, et al. (2002) Studies on the immuno-Modulating and antitumor activities ofGanodermalucidum(Reishi) polysaccharides: functional and proteomic analyses of a fucose-Containing glycoprotein fraction responsible for the activities. Bioorgan Med Chem 10:1057-1062
  133. Gao Y, Gao H, Chan E, Tang W, Xu A, et al. (2005) Antitumor activity and underlying mechanisms of ganopoly, the refined polysaccharides extracted from Ganodermalucidum, in mice. Immunol Invest 34: 171-198.
  134. Bao X, Liu C, Fang J, Li X (2001) Structural and immunological studies of a major polysaccharide from spores of Ganodermalucidum (Fr.) Karst. Carbohydr Res 332: 67-74.
  135. Bao XF, Wang XS, Dong Q, Fang JN, Li XY (2002) Structural features of immunologically active polysaccharides from Ganodermalucidum. Phytochemistry 59: 175-181.
  136. Ooi LS, Liu F, Ooi VE, Ng TB, Fung MC (2002) Gene expression of immunomodulatory cytokines induced by Narcissus tazettalectin in the mouse. Biochem Cell Biol 80: 271-277.
  137. Wang YY, Khoo KH, Chen ST, Lin CC, et al. (2002) Studies on the immuno-modulating and antitumor activities of Ganodermalucidum (Reishi) polysaccharides: functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 10:1057-1062
  138. Zhang GL, Wang YH, Ni W, Teng HL, Lin ZB (2002) Hepatoprotective role of Ganodermalucidum polysaccharide against BCG-induced immune liver injury in mice. World J Gastroenterol 8: 728-733.
  139. Cao QZ, Lin ZB (2004) Antitumor and anti-angiogenic activity of Ganodermalucidum polysaccharides peptide. ActaPharmacol Sin 25: 833-838.
  140. Li WJ, Chen Y, Nie SP, Xie MY, He M, et al. (2011) Ganodermaatrum polysaccharide induces anti-tumor activity via the mitochondrial apoptotic pathway related to activation of host immune response. J Cell Biochem 112: 860-871.
  141. Zhao HB, Lin SQ, Liu JH, Lin ZB (2004) Polysaccharide extract isolated from ganodermalucidum protects rat cerebral cortical neurons from hypoxia/reoxygenation injury. J PharmacolSci 95: 294-298.
  142. He CY, Li WD, Guo SX, Lin SQ, Lin ZB (2006) Effect of polysaccharides from Ganodermalucidum on streptozotocin-induced diabetic nephropathy in mice. J Asian Nat Prod Res 8: 705-711.
  143. Meng G, Zhu H, Yang S, Wu F, et al. (2011) Attenuating effects of Ganodermalucidum polysaccharides on myocardial collagen cross-linking relates to advanced glycation end product and antioxidant enzymes in high-fat-diet and streptozotocin-induced diabetic rats. CarbohydPolym 84:180-185
  144. Ohno N, Adachi Y, Suzuki I, Sato K, Oikawa S, et al. (1986) Characterization of the antitumor glucan obtained from liquid-cultured Grifolafrondosa. Chem Pharm Bull (Tokyo) 34: 1709-1715.
  145. Lee BC, Bae JT, Pyo HB, Choe TB, et al. (2003) Biological activities of the polysaccharides produced from submerged culture of the edible BasidiomyceteGrifolafrondosa. Enzyme Microb Tech 32:574-581
  146. Tsao YW, Kuan YC, Wang JL, Sheu F (2013) Characterization of a novel maitake (Grifolafrondosa) protein that activates natural killer and dendritic cells and enhances antitumor immunity in mice. J Agric Food Chem 61: 9828-9838.
  147. Lei H, Zhang M, Wang Q, Guo S, et al. (2013) MT-alpha-glucan from the fruit body of the maitake medicinal mushroom Grifolafrondosa (higher Basidiomyetes) shows protective effects for hypoglycemic pancreatic beta-cells. Int J Med Mushrooms 15:373-381
  148. Masuda Y, Inoue H, Ohta H, Miyake A, et al. (2013) Oral administration of soluble beta-glucans extracted from Grifolafrondosa induces systemic antitumor immune response and decreases immunosuppression in tumor-bearing mice. Int J Cancer 133:108-119
  149. Preuss HG, Echard B, Fu J, Perricone NV, Bagchi D, et al. (2012) Fraction SX of maitake mushroom favorably influences blood glucose levels and blood pressure in streptozotocin-induced diabetic rats. J Med Food 15: 901-908.
  150. Han C, Cui B (2012) Pharmacological and pharmacokinetic studies with agaricoglycerides, extracted from Grifolafrondosa, in animal models of pain and inflammation. Inflammation 35: 1269-1275.
  151. Sato M, Tokuji Y, Yoneyama S, Fujii-Akiyama K, Kinoshita M, et al. (2013) Effect of dietary Maitake (Grifolafrondosa) mushrooms on plasma cholesterol and hepatic gene expression in cholesterol-fed mice. J Oleo Sci 62: 1049-1058.
  152. Shi ZW, Liu Y2, Xu Y1, Hong YR1, Liu Q1, et al. (2014) Tremella Polysaccharides attenuated sepsis through inhibiting abnormal CD4�CD25(high) regulatory T cells in mice. Cell Immunol 288: 60-65.
  153. Xu W, Shen X, Yang F, Han Y, Li R, et al. (2012) Protective effect of polysaccharides isolated from Tremellafuciformis against radiation-induced damage in mice. J Radiat Res 53: 353-360.
  154. Kiho T, Tsujimura Y, Sakushima M, Usui S, Ukai S (1994) [Polysaccharides in fungi. XXXIII. Hypoglycemic activity of an acidic polysaccharide (AC) from Tremellafuciformis]. YakugakuZasshi 114: 308-315.
  155. Hsu S, Chan S, Weng C, Yang S, et al. (2013) Long-Term Regeneration and Functional Recovery of a 15?mm Critical Nerve Gap Bridged by Tremellafuciformis Polysaccharide-Immobilized Polylactide Conduits. Evi-bascomplealter medicine, 1-12.
  156. Park H, Park KJ, Yeo IH, Shim I, et al. (2012) Tremellafuciformis enhances the neurite outgrowth of PC12 cells and restores trimethyltin-induced impairment of memory in rats via activation of CREB transcription and cholinergic systems. Behav Brain Res 229:82-90
  157. Kim JH, Ha HC, Lee MS, Kang JI, Kim HS, et al. (2007) Effect of Tremellafuciformis on the neurite outgrowth of PC12h cells and the improvement of memory in rats. Biol Pharm Bull 30: 708-714.
  158. Cheng HH, Hou WC, Lu ML (2002) Interactions of lipid metabolism and intestinal physiology with Tremellafuciformis Berk edible mushroom in rats fed a high-cholesterol diet with or without Nebacitin. J Agric Food Chem 50: 7438-7443.
  159. KaylorMJ Path to radiant health. Maitake D-fraction The Mushroom World’s Gift for Today.
  160. Nakata M, Tang W (2008) Japan-China Joint Medical Workshop on Drug Discoveries and Therapeutics 2008: The need of Asian pharmaceutical researchers' cooperation. Drug DiscovTher 2: 262-263.
  161. Liu A, Zang LH, Sun QJ (2008) Clinical observation of effect on GrifolaFrondosa Amylose against tumor. Shandong Institute of Light Industry: Science and Technology 22:43-45
  162. Motohiro N (1981) Studies on fungal polysaccharides. XXVII. Structural examination of a water-soluble, antitumor polysaccharide of Ganodermalucidum. Chem Pharm Bull 29:3611-3616
  163. Sone Y, Okuda R, Wada N, Kishida E, et al. (1985) Structures and antitumor activities of the polysaccharides isolated from fruiting body and the growing culture of mycelium of Ganodermalucidum. Agricultural and Biological Chemistry 49:2641-2653
  164. Chen J, Zhou J, Zhang L, Nakamura Y, et al. (1998) Chemical structure of the water-insoluble polysaccharide isolated from the fruiting body of Ganodermalucidum. Polym J 30:838-842
  165. Li Y, Fang L, Zhang K (2007) Structure and bioactivities of a galactose rich extracellular polysaccharide from submergedly culturedGanodermalucidum. CarbohydPolym 68:323-328
  166. Ye L, Zhang J, Zhou K, Yang Y, Zhou S, et al. (2008) Purification, NMR study and immunostimulating property of a fucogalactan from the fruiting bodies of Ganodermalucidum. Planta Med 74: 1730-1734.
  167. Ye L, Zhang J, Ye X, Tang Q, Liu Y, et al. (2008) Structural elucidation of the polysaccharide moiety of a glycopeptide (GLPCW-II) from Ganodermalucidum fruiting bodies. Carbohydr Res 343: 746-752.
  168. Ye L, Zhang J, Yang Y, Zhou S, et al. (2009) Structural characterisation of a heteropolysaccharide by NMR spectra. Food Chem 112:962-966
  169. Liu W, Wang H, Pang X, Yao W, Gao X (2010) Characterization and antioxidant activity of two low-molecular-weight polysaccharides purified from the fruiting bodies of Ganodermalucidum. Int J BiolMacromol 46: 451-457.
  170. Ye L, Li J, Zhang J, Pan Y (2010) NMR characterization for polysaccharide moiety of a glycopeptide. Fitoterapia 81: 93-96.
  171. Huang SQ, Li JW, Li YQ, Wang Z (2011) Purification and structural characterization of a new water-soluble neutral polysaccharide GLP-F1-1 from Ganodermalucidum. Int J BiolMacromol 48: 165-169.
  172. Dong Q, Wang Y, Shi L, Yao J, Li J, et al. (2012) A novel water-soluble β-D-glucan isolated from the spores of Ganodermalucidum. Carbohydr Res 353: 100-105.
  173. You YH, Lin ZB (2002) Protective effects of Ganodermalucidum polysaccharides peptide on injury of macrophages induced by reactive oxygen species. ActaPharmacol Sin 23: 787-791.
  174. Hamuro J, Röllinghoff M, Wagner H (1980) Induction of cytotoxic peritoneal exudate cells by T-cell immune adjuvants of the beta(1 leads to 3) glucan-type lentinan and its analogues. Immunology 39: 551-559.
  175. Li X, Xu W (2011) TLR4-mediated activation of macrophages by the polysaccharide fraction from Polyporusumbellatus(pers.) Fries. J Ethnopharmacol 135: 1-6.
  176. Zhao YY, Zhang L, Mao JR, Cheng XH, Lin RC, et al. (2011) Ergosta-4,6,8(14),22-tetraen-3-one isolated from Polyporusumbellatus prevents early renal injury in aristolochic acid-induced nephropathy rats. J Pharm Pharmacol 63: 1581-1586.
  177. Zhang G, Zeng X, Li C, Li J, Huang Y, et al. (2011) Inhibition of urinary bladder carcinogenesis by aqueous extract of sclerotia of Polyporusumbellatus fries and polyporus polysaccharide. Am J Chin Med 39: 135-144.
  178. Zhang G, Zeng X, Han L, Wei JA, Huang H (2010) Diuretic activity and kidney medulla AQP1, AQP2, AQP3, V2R expression of the aqueous extract of sclerotia of Polyporusumbellatus FRIES in normal rats. J Ethnopharmacol 128: 433-437.
  179. Yang BK, Gu YA, Jeong YT, Jeong H, Song CH (2007) Chemical characteristics and immuno-modulating activities of exo-biopolymers produced by Grifolafrondosa during submerged fermentation process. Int J BiolMacromol 41: 227-233.
Citation: Zhou Z, Han Z, Zeng Y, Zhang M, Cui Y, et al. (2014) Chinese FDA Approved Fungal Glycan-Based Drugs: An Overview of Structures, Mechanisms and Clinical Related Studies. Transl Med 4:141.

Copyright: © 2014 Zhou Z, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Top

https://sekillinickyazma.com.tr/